NMS-P293|NMS P-293;NMS P293

Cas No.:	1606996-12-6
Chemical Name:	NMS-P293
Synonyms:	NMSP293，NMS P293
SMILES:	O=C(C1=CC=CC(CN2C3CCN(C4CCCCC4)CC3)=C1C2=O)N
Formula:	₃₄₁^.₄₅
M.Wt:	C20H27N3O2
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

NMS-P293 is a novel potent and selective PARP-1 inhibitor possessing >200-fold selectivity versus PARP-2; NMS-P293 inhibits hydrogen peroxide induced poly ADP-ribose (PAR) synthesis with an IC50 in the single digit nanomolar range; possesses favorable ADME properties, causes complete tumor regressions in mice bearing BRCA mutated breast cancer xenografts.

Cat. No.	Product name	Field of application
DC21390	NMS-P293	NMS-P293 (also known as NMS-03305293) is an innovative, second-generation oral small molecule inhibitor specifically targeting PARP1. Developed by Nerviano Medical Sciences, it distinguishes itself from first-generation PARP inhibitors through its high selectivity for PARP1 over PARP2, which significantly reduces hematological toxicities like bone marrow suppression.A defining feature of NMS-P293 is its non-trapping mechanism; by inhibiting enzyme activity without trapping PARP on DNA, it offers a superior safety profile that allows for effective combination with DNA-damaging chemotherapies. Furthermore, it possesses exceptional blood-brain barrier (BBB) permeability, making it a leading candidate for treating primary CNS tumors like glioblastoma and brain metastases.